Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Ulbright-Hodes syndrome is characterized by renal dysplasia, growth retardation, phocomelia or mesomelia, radiohumeral fusion, rib abnormalities, anomalies of the external genitalia and a potter-like facies. The syndrome has been described in three infants (one pair of sibs and an unrelated case), all of whom died shortly after birth from respiratory distress resulting from pulmonary hypoplasia and oligohydramnios caused by renal dysplasia. The mode of transmission appears to be autosomal recessive.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for Ulbright-Hodes syndrome.
50 publications have been identified in PubMed for Ulbright-Hodes syndrome. Research spans Case Report / Case Series (40%), Review / Meta-Analysis (28%), and Basic Science / Preclinical (20%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 20 | 40% |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 5:49 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Ulbright-Hodes syndrome
14 |
28% |
Laboratory research | 10 | 20% |
Disease patterns and progression | 4 | 8% |
New treatment approaches | 2 | 4% |
Oe K (2026). [PMID: 41512743](https://pubmed.ncbi.nlm.nih.gov/41512743/). *Clin Lung Cancer*. [Case Report / Case Series]
Ye W (2026). [PMID: 41832144](https://pubmed.ncbi.nlm.nih.gov/41832144/). *Nat Commun*. [Basic Science / Preclinical]
Chang H (2026). [PMID: 42042039](https://pubmed.ncbi.nlm.nih.gov/42042039/). *Curr Issues Mol Biol*. [Review / Meta-Analysis]
Jamal F (2026). [PMID: 41748253](https://pubmed.ncbi.nlm.nih.gov/41748253/). *BMJ Case Rep*. [Case Report / Case Series]
Leiter SM (2026). [PMID: 41933220](https://pubmed.ncbi.nlm.nih.gov/41933220/). *J Cancer Res Clin Oncol*. [Basic Science / Preclinical]
Wang X (2026). [PMID: 41922188](https://pubmed.ncbi.nlm.nih.gov/41922188/). *Zhejiang Da Xue Xue Bao Yi Xue Ban*. [Review / Meta-Analysis]
Roskoski R Jr (2026). [PMID: 42107510](https://pubmed.ncbi.nlm.nih.gov/42107510/). *Pharmacol Res*. [Review / Meta-Analysis]
Zhang J (2026). [PMID: 41489004](https://pubmed.ncbi.nlm.nih.gov/41489004/). *J Mater Chem B*. [Review / Meta-Analysis]
Fujishiro H (2026). [PMID: 41787834](https://pubmed.ncbi.nlm.nih.gov/41787834/). *J Appl Toxicol*. [Basic Science / Preclinical]
Xiong F (2026). [PMID: 42097338](https://pubmed.ncbi.nlm.nih.gov/42097338/). *J Ethnopharmacol*. [Basic Science / Preclinical]